Dr. Michael Lewitt presented on current and emerging treatments for skin conditions like atopic dermatitis and itch. He opened the panel by discussing FDA-approved drugs such as roflumilast, dupilumab, and lebrikizumab and how they fit into the treatment equation. His portion of the presentation also highlighted pipeline developments, including bi-specific and tri-specific targeted therapies as well as an IL-2 agonist. Finally, the panel concluded with case studies covering family planning considerations and treatment strategies across various pediatric age groups.